Application of traditional Chinese medicine composition in preparation of medicine for intestinal obstruction

Abstract

The invention relates to an application of a traditional Chinese medicine composition in preparation of medicines for intestinal obstruction, which is characterized in that the traditional Chinese medicine composition is prepared from angelica sinensis, achyranthes bidentata, cistanche, rhizoma alismatis, cimicifugae foetidae and fructus aurantii. The composition disclosed by the invention can be used for relieving inflammatory response in a rat with incomplete intestinal obstruction and has an intestinal barrier protection function; for postoperative intestinal obstruction mice, the reduction of the small intestine propulsion rate of the mice can be obviously reversed, and the expression level of inflammatory factors is reduced. The traditional Chinese medicine composition has a good treatment effect on intestinal obstruction.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, relates to a new use of a traditional Chinese medicine composition, and particularly relates to the use of the traditional Chinese medicine composition in preparing a medicine for intestinal obstruction. Background Art

[0002] Intestinal obstruction refers to a pathological condition in which the intestinal contents cannot pass through the intestine normally due to various reasons, resulting in increased pressure in the intestinal cavity and intestinal dysfunction. Intestinal obstruction is a common surgical acute abdomen. The incidence rate has been on the rise in recent years, and its causes are complex and diverse. Western medicine treatment mainly focuses on surgical relief of obstruction and conservative support, but the postoperative recurrence rate is high, especially the mortality rate of strangulated intestinal obstruction is still as high as 5%-30%. Postoperative intestinal obstruction does not mean complete obstruction of the intestine, but rather that the function of the intestine (especially peristalsis) is temporarily suppressed or impaired, resulting in the inability of the intestinal contents to advance normally, forming symptoms of incomplete intestinal obstruction.

[0003] Traditional Chinese medicine (TCM) offers unique advantages in treating intestinal obstruction, especially for incomplete intestinal obstruction. Through syndrome differentiation and treatment, TCM uses prescriptions combined with external treatments such as enemas and acupoint application to effectively promote intestinal motility, improve local blood circulation, and regulate overall body function to reduce the risk of recurrence. Compared to surgical trauma, TCM therapies have fewer side effects and are more safe, making them suitable for postoperative rehabilitation and the elderly and frail. Modern research has also confirmed that TCM can exert its therapeutic effects through multiple pathways, such as regulating the intestinal microbiome and inhibiting inflammatory responses. TCM not only alleviates symptoms but also promotes the resolution of inflammation. Therefore, it is crucial to identify TCM therapies that can be used to prevent and treat intestinal obstruction. Summary of the Invention

[0004] To address the above technical problems, the present invention provides a use of a traditional Chinese medicine composition in the preparation of a medicament for treating intestinal obstruction. The traditional Chinese medicine composition is prepared from angelica sinensis, Achyranthes bidentata, Cistanche deserticola, Alismatis rhizome, Cimicifuga heracleifolia, and Fructus aurantii. The use can be any method that is beneficial to improving the corresponding symptoms of the patient, including treatment or prevention.

[0005] Specifically, the intestinal obstruction may be incomplete intestinal obstruction, especially postoperative intestinal obstruction, the symptoms of which include abdominal distension, vomiting, abdominal pain and / or reduced or stopped flatulence and defecation.

[0006] Furthermore, the Chinese medicine composition comprises: 1-100 parts of Chinese Angelica sinensis, 1-100 parts of Achyranthes bidentata, 1-100 parts of Cistanche deserticola, 1-100 parts of Rhizoma Alismatis, 1-100 parts of Cimicifuga heracleifolia, and 1-100 parts of Fructus Aurantii Immaturus. The composition of the present invention can be directly ground into a powder or can be an extract prepared by conventional means in the art. The Chinese herbs used in the composition of the present invention can also be used in the form of direct grinding into a powder, an extract, or other processed forms.

[0007] Furthermore, the traditional Chinese medicine composition comprises: 1-30 parts of angelica sinensis, 1-16 parts of Achyranthes bidentata, 1-20 parts of Cistanche deserticola, 1-12 parts of Alisma orientalis, 1-6 parts of Cimicifuga heracleifolia, and 1-8 parts of Citrus aurantium.

[0008] Optionally, the Chinese medicine composition is composed of the following components: 10-15 parts of Chinese Angelica sinensis, 7-10 parts of Achyranthes bidentata, 7-10 parts of Cistanche deserticola, 5-8 parts of Rhizoma Alismatis, 2-3 parts of Cimicifuga heracleifolia, and 3-5 parts of Fructus Aurantii Immaturus. Among them, 10-15 parts can be 11, 12, 13, 14 parts, etc., 7-10 parts can be 8 or 9 parts, 5-8 parts can be 6 or 7 parts, 2-3 parts can be 2.5 parts, and 3-5 parts can be 4 parts; but the present invention is not limited to the listed values, and other values not listed within the numerical range are also applicable, and other numerical ranges herein can also be understood in the same way.

[0009] Preferably, the traditional Chinese medicine composition comprises: 14.92 parts of angelica sinensis, 7.46 parts of Achyranthes bidentata, 9.33 parts of Cistanche deserticola, 5.60 parts of Alisma orientalis, 2.61 parts of Cimicifuga heracleifolia, and 3.73 parts of Citrus aurantium.

[0010] In some embodiments, pharmaceutically acceptable excipients are also included. Specifically, the excipients used are carriers or excipients commonly used in the art, including but not limited to starch, lactose, glucose, sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, malt, gelatin, polyols (such as propylene glycol, glycerol, mannitol), compressed tablets, etc., to help improve the stability or activity of the drug, or to produce an acceptable taste or smell when taken orally.

[0011] Specifically, the aforementioned medicine is selected from decoctions, granules, capsules, tablets, oral liquids, pills, soft capsules, dripping pills, tinctures, syrups, suppositories, gels, sprays, and injections.

[0012] The present invention also proposes a preparation method of the above-mentioned traditional Chinese medicine composition: take six medicinal materials including angelica, Achyranthes bidentata, Cistanche deserticola, Alismatis rhizome, Cimicifuga heracleifolia and Fructus Aurantii Immaturus, add 8 times the amount of water, reflux extraction for 40 minutes, filter, and concentrate the filtrate into an extract.

[0013] The present invention also provides a method for preparing the aforementioned drug for treating or preventing intestinal obstruction, wherein the drug is selected from granules, and the preparation method thereof is as follows:

[0014] a. Take angelica, Achyranthes, Cistanche, Alisma, Cimicifuga, Citrus aurantium six herbs, add 8 times the amount of water, reflux extraction for 40 minutes, filter, and concentrate the filtrate into an extract;

[0015] b. Take the above extract, spray dry it, grind it into a fine powder, mix it, and spray-dry the fine powder. Add an appropriate amount of dextrin and steviol glycosides and granulate it.

[0016] The present invention also proposes the use of a traditional Chinese medicine composition in the preparation of a drug for promoting intestinal motility, intestinal barrier protection and / or for intestinal obstruction inflammatory response. The traditional Chinese medicine composition is prepared by weight from the following components: 1-100 parts of angelica sinensis, 1-100 parts of Achyranthes bidentata, 1-100 parts of Cistanche deserticola, 1-100 parts of Alisma orientalis, 1-100 parts of Cimicifuga heracleifolia, and 1-100 parts of Cimicifugae.

[0017] Furthermore, the traditional Chinese medicine composition comprises: 1-30 parts of angelica sinensis, 1-16 parts of Achyranthes bidentata, 1-20 parts of Cistanche deserticola, 1-12 parts of Alisma orientalis, 1-6 parts of Cimicifuga heracleifolia, and 1-8 parts of Citrus aurantium.

[0018] Optionally, the traditional Chinese medicine composition is composed of the following components: 10-15 parts of angelica sinensis, 7-10 parts of Achyranthes bidentata, 7-10 parts of Cistanche deserticola, 5-8 parts of Alisma orientalis, 2-3 parts of Cimicifuga heracleifolia, and 3-5 parts of Citrus aurantium.

[0019] Preferably, the traditional Chinese medicine composition comprises: 14.92 parts of angelica sinensis, 7.46 parts of Achyranthes bidentata, 9.33 parts of Cistanche deserticola, 5.60 parts of Alisma orientalis, 2.61 parts of Cimicifuga heracleifolia, and 3.73 parts of Citrus aurantium.

[0020] Furthermore, when the drug is selected from granules, its preparation method is as follows:

[0021] a. Take angelica, Achyranthes, Cistanche, Alisma, Cimicifuga, Citrus aurantium six herbs, add 8 times the amount of water, reflux extraction for 40 minutes, filter, and concentrate the filtrate into an extract;

[0022] b. Take the above extract, spray dry it, grind it into a fine powder, mix it, and spray-dry the fine powder. Add an appropriate amount of dextrin and steviol glycosides and granulate it.

[0023] The composition of the present invention can alleviate inflammatory responses in rats and has intestinal barrier protection. It also significantly reverses the reduction in small intestinal propulsion rate in mice and reduces the expression of inflammatory factors. This suggests that the Chinese medicine composition can significantly inhibit the development of inflammation, improve gastrointestinal motility, and has a good therapeutic effect on intestinal obstruction. DETAILED DESCRIPTION

[0024] As mentioned above, the present invention aims to provide a use of a traditional Chinese medicine composition in the preparation of a medicament for treating intestinal obstruction. Detailed description will be given below in conjunction with specific experimental content.

[0025] Unless otherwise specified, the following experiments were conducted under conventional conditions or those recommended by the manufacturer. All APIs, excipients, reagents, and instruments used, for which the manufacturer is not specified, are commercially available. Unless otherwise specified, all percentages, ratios, proportions, and parts are by weight. Unless otherwise specified, the medicinal materials of this invention may be raw or processed, provided that this does not significantly affect the overall efficacy of the formulation.

[0026] Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention.

[0027] Example 1 Preparation of Chinese medicine composition

[0028] Raw material composition: Angelica sinensis 1492g, Achyranthes bidentata 746g, Cistanche deserticola 933g, Alisma orientale 560g, Cimicifuga heracleifolia 261g, Cimicifugae fructus 373g.

[0029] The preparation method of the Chinese medicine composition granules is as follows:

[0030] a Take angelica, Achyranthes, Cistanche, Zexie, Cimicifuga, Citrus aurantium six herbs, add 8 times the amount of water, reflux extraction for 40 minutes, filtered, and the filtrate was concentrated to an extract to obtain a Chinese medicine composition;

[0031] b. Take the above extract, spray dry it, grind it into a fine powder, mix it, and spray-dry the fine powder. Add an appropriate amount of dextrin and steviol glycosides and granulate it.

[0032] Experimental Example 2 Effect of Chinese herbal medicine composition on rats with incomplete intestinal obstruction

[0033] 1. Experimental Materials

[0034] 1.1 Animals

[0035] SPF grade SD rats, half male and half female, weighing 160-180 g, were purchased from Sibeifu (Suzhou) Biotechnology Co., Ltd. after adaptive feeding.

[0036] 1.2 Medication

[0037] The Chinese medicine composition prepared in Example 1 was manufactured by Jiangsu Kangyuan Pharmaceutical Co., Ltd.

[0038] Mosapride citrate tablets, Chengdu Kanghong Pharmaceutical Group Co., Ltd., batch number: 20240227;

[0039] Zotazone@50, Virbac Co., Ltd., France, specifications: tiletamine 125 mg + zolazepam 125 mg, batch number: BN9AB4A;

[0040] SumianxinⅡ, Shengda Animal Pharmaceutical Co., Ltd., specification: 2ml: 0.2g, batch number: 202340503;

[0041] Sodium chloride injection, Sichuan Kelun Pharmaceutical Co., Ltd., specification: 500 ml / bottle, batch number: B24021406;

[0042] Iodine disinfectant, Shandong Lierkang Medical Technology Co., Ltd., specification: 100 ml / bottle, batch number: 20240201A;

[0043] Rat IL-6 (Interleukin 6) ELISA Kit, Elabscience, specification: 96T, batch number PJL8MRL2ZZ.

[0044] Rat TNF-α Quantikine ELISA, RD, specification: 96T, batch number: P370795.

[0045] 1.3 Instruments

[0046] BSA224S-CW electronic balance, Sartorius; TC3K weight scale, G&G; CENTRFUGE5840 refrigerated centrifuge, Eppendorf; BCD-216SZ refrigerator, Haier; Flexstation 3 microplate reader, Meigu Molecular Biology, USA.

[0047] 2. Dosage design

[0048] The daily dosage of the traditional Chinese medicine composition is 43.65g of the crude drug per day. Based on the body surface area conversion method, the equivalent dose for rats is 43.65g of crude drug / 60kg * 6.2 = 4.51g of crude drug / kg, which is used as the medium dose. Using a 0.5:1:2 dosing regimen, the low dose is 2.26g of crude drug / kg and the high dose is 9.02g of crude drug / kg. The clinical daily dosage of mosapride citrate is 15mg, which translates to an equivalent dose of 1.6mg for rats.

[0049] 3. Experimental Methods

[0050] 3.1 Grouping and modeling

[0051] SPF Sprague-Dawley rats (half male and half female) were randomly divided into sham-operated, model, mosapride citrate, and high-, medium-, and low-dose groups of the traditional Chinese medicine composition, with 10 rats in each group. The experiments began after one week of acclimatization. Rats were fasted for 12 hours preoperatively. Rats were anesthetized with 40 mg / kg of Sootai@50 plus 5 mg / kg of Sumenxin II. After abdominal skin preparation and disinfection with iodine, an approximately 2.5 cm incision was made 0.5-1 cm to the right of the midline of the abdomen. The ileocecal region was exposed by layer-by-layer incision. A latex drainage tube with an inner diameter of 0.6-0.7 cm and a width of 0.6 cm was cut to create a loop. The mesentery was penetrated at the ileum 3-5 cm from the ileocecal region, and the loop was placed over the intestine. The loop was sutured at both ends to create an incomplete intestinal obstruction model. The intestinal tube was returned to the abdominal cavity, and the abdomen was closed. Rats in the sham-operated group were anesthetized, the abdomen was opened, and the mesentery was penetrated at the same location, and the abdomen was closed. The technique should be gentle throughout the entire process to reduce irritation to the intestinal tract. The operation strictly follows the principles of aseptic operation, and routine feeding is carried out after the operation.

[0052] 3.2 Administration

[0053] After modeling, rats in each group were given medication for four consecutive days. The model control and sham-operated groups were given normal saline, the positive drug group was gavaged with mosapride citrate solution, and the high-, medium-, and low-dose groups of the Chinese medicine composition were given corresponding concentrations of the Chinese medicine composition solution, with the gavage volume of 10 mL / kg. After each gavage, routine disinfection with iodine was performed, and the bedding was kept dry and comfortable to prevent wound infection in the rats' cages.

[0054] 3.3 Index detection

[0055] Six hours after the last administration, blood was collected from the abdominal aorta of the rats, collected in anticoagulant tubes, and allowed to stand at room temperature for 0.5 hours before centrifugation at 3000 rpm for 10 minutes. The supernatant was collected and stored in a refrigerator at -20°C. ELISA was used to determine the expression levels of IL-6 and TNF-α in rat serum.

[0056] 3.4 Data Analysis

[0057] All quantifiable data were expressed as x ± SD, and data were compared between groups using analysis of variance and T test. p < 0.05 indicated statistically significant differences.

[0058] 4. Experimental results

[0059] The results showed that, as shown in Table 1, the serum IL-6 and TNF-α levels in the model group were significantly higher than those in the sham group (p < 0.001), indicating that the model was successfully established. Compared with the model group, the serum IL-6 and TNF-α levels in the high-, medium-, and low-dose groups of the Chinese medicine composition were all lower than those in the model group (p < 0.001, 0.01, and 0.05, respectively), indicating that the high-, medium-, and low-dose Chinese medicine composition can reduce the serum IL-6 and TNF-α levels in rats with incomplete intestinal obstruction. This suggests that the Chinese medicine composition can reduce the levels of inflammatory factors in rats with incomplete intestinal obstruction, alleviate the inflammatory response in rats, and have intestinal barrier protection function.

[0060] Table 1 Serum IL-6 and TNF-α levels (ng / L) in rats of each group

[0061]

[0062] Note: Compared with the sham operation group, ### P<0.001; compared with the model group, *P<0.05, **P<0.01, ***P<0.001.

[0063] Experimental Example 3 Effect of Chinese herbal medicine composition on mice with postoperative intestinal obstruction

[0064] 1. Experimental Materials

[0065] 1.1 Animals

[0066] SPF grade C57BL / 6J males weighing 22-24 g were purchased from SPIEF (Suzhou) Biotechnology Co., Ltd. after adaptive feeding and were prepared for the experiment.

[0067] 1.2 Medication

[0068] The intermediate of the Chinese medicine composition prepared in Example 1, Jiangsu Kangyuan Pharmaceutical Co., Ltd.;

[0069] Mosapride citrate tablets, Chengdu Kanghong Pharmaceutical Group Co., Ltd., batch number: 20240227;

[0070] Zotazone@50, Virbac Co., Ltd., France, specifications: tiletamine 125 mg + zolazepam 125 mg, batch number: BN9AB4A;

[0071] SumianxinⅡ, Shengda Animal Pharmaceutical Co., Ltd., specification: 2ml: 0.2g, batch number: 202340503;

[0072] Sodium chloride injection, Sichuan Kelun Pharmaceutical Co., Ltd., specification: 500 ml / bottle, batch number: B24021406;

[0073] Iodine disinfectant, Shandong Lierkang Medical Technology Co., Ltd., specification: 100 ml / bottle, batch number: 20240201A;

[0074] Gum Arabic powder, Shenggong, specification: 100g / bottle, batch number: 20210302;

[0075] Edible activated carbon powder, Shenggong, specification: 1KG / box, batch number: 20201125;

[0076] Mouse IL-6 ELISA Kit, invitrogen, specification: 96T, batch number: 247648-002;

[0077] Mouse TNF alpha Uncoated ELISA Kit, invitrogen, specification: 96T, lot number: 248922-003.

[0078] 1.3 Instruments

[0079] BSA224S-CW electronic balance, Sartorius; TC3K weight scale, G&G; CENTRFUGE5840 refrigerated centrifuge, Eppendorf; BCD-216SZ refrigerator, Haier; Flexstation 3 microplate reader, Meigu Molecular Biology, USA.

[0080] 2. Dosage design

[0081] The daily dosage of the traditional Chinese medicine composition is 43.65g of the crude drug per day. Based on the body surface area conversion method, the equivalent dose for mice is 43.65g of crude drug / 60kg * 12.3 = 8.95g of crude drug / kg, which is considered the medium dose. Using a 0.5:1:2 dosing regimen, the low dose is 4.47g of crude drug / kg and the high dose is 17.90g of crude drug / kg. The clinical daily dosage of mosapride citrate is 15mg, which translates to an equivalent dose of 3.1mg for mice.

[0082] 3. Experimental Methods

[0083] 3.1 Grouping and modeling

[0084] SPF male C57BL / 6J mice were randomly divided into a normal group, a model group, a mosapride citrate group, and groups receiving high, medium, and low doses of the traditional Chinese medicine composition, with 10 mice per group. All mice, except the normal group, were fasted for 24 hours before undergoing the experiment. A classic small bowel disruption procedure was used to establish a postoperative intestinal obstruction model in mice. Mice were anesthetized with an intraperitoneal injection of 55 mg / kg of Shutai@50 plus 10 mg / kg of Sumenxin II. The mice were placed supine on the operating table, hair removed, and disinfected. The abdominal cavity was opened along the linea alba, and a sterile gauze drape was placed over the mouse abdomen. Two sterile cotton swabs moistened with saline were used to gently remove a segment of small intestine from the abdominal cavity and place it on the gauze. The small intestine was then gently rolled back and forth and squeezed three times from the proximal jejunum to the terminal ileum, taking approximately 15 minutes. After the stimulation was completed, the small intestine was returned to the abdominal cavity and sutured. During the procedure, care was taken to maintain intestinal warmth to prevent ischemia and necrosis.

[0085] 3.2 Administration

[0086] Each group of mice was administered 6 hours after surgery. The normal group and the model group were given normal saline, the positive drug group was gavaged with mosapride citrate solution, and the high-, medium-, and low-dose groups of the Chinese medicine composition were given the corresponding concentrations of the Chinese medicine composition solution, and the gavage volume was 20 mL / kg.

[0087] 3.3 Index detection

[0088] 23.5 hours after surgery, mice were gavaged with a charcoal powder complex (10% gum arabic + 10% edible activated charcoal powder, 10 mL / kg). Thirty minutes later, mice were enucleated and sacrificed by cervical dislocation. The entire small intestine was removed, and the total length and distance of charcoal powder propagation were measured. The intestinal propagation rate (%) was calculated as: distance propagated by charcoal powder in the small intestine / total intestinal length × 100%. The samples were centrifuged at 3000 rpm for 10 minutes, and the supernatant was collected and stored at -20°C. Serum levels of IL-6 and TNF-α were assayed by ELISA.

[0089] 3.4 Data Analysis

[0090] All quantifiable data were expressed as x ± SD, and data were compared between groups using analysis of variance and T test. p < 0.05 indicated statistically significant differences.

[0091] 4. Experimental results

[0092] 4.1 Effects on intestinal propulsion rate in mice

[0093] As shown in Table 2, compared with the normal group, the small intestinal propulsion rate of mice in the model group was significantly reduced 24 hours after surgery (p<0.001); compared with the model group, the small intestinal propulsion rate of the high, medium and low dose groups of mosapride citrate and the Chinese medicine composition was significantly reversed (p<0.001, p<0.05).

[0094] Table 2 Small intestinal propulsion rate of mice in each group (%)

[0095]

[0096] Note: Compared with the sham operation group, ### P<0.001; compared with the model group, *P<0.05, ***P<0.001.

[0097] 4.2 Effects on serum proinflammatory factors IL-6 and TNF-α

[0098] As shown in Table 3, serum IL-6 and TNF-α levels in the model group were significantly higher than those in the normal group (p < 0.001), indicating successful model establishment. Compared with the model group, serum IL-6 and TNF-α levels in the high-, medium-, and low-dose mosapride citrate and TCM composition groups were all lower (p < 0.001, 0.05), indicating that high-, medium-, and low-dose TCM compositions were able to reduce serum IL-6 and TNF-α levels in mice with postoperative intestinal obstruction. This suggests that TCM compositions can reduce inflammatory cytokine levels in mice with postoperative intestinal obstruction and alleviate inflammatory responses in mice.

[0099] Table 3 Serum IL-6 and TNF-α levels (ng / L) of mice in each group

[0100]

[0101]

[0102] Note: Compared with the sham operation group, ### P<0.001; compared with the model group, *P<0.05, ***P<0.001.

[0103] The above embodiments of the present invention are merely examples for the purpose of clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. Those skilled in the art will appreciate that other variations or modifications may be made based on the above description. It is not necessary and impossible to enumerate all embodiments here. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the claims of the present invention.

Claims

1. Use of a traditional Chinese medicine composition in the preparation of a drug for intestinal obstruction, characterized in that: The traditional Chinese medicine composition is prepared from the following components by weight: 1-100 parts of angelica sinensis, 1-100 parts of cyperus rotundus, 1-100 parts of cistanche deserticola, 1-100 parts of oriental rhizome, 1-100 parts of cimicifuga heracleifolia, and 1-100 parts of fructus aurantii.

2. The use according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following components: 1-30 parts of angelica sinensis, 1-16 parts of cyperus rotundus, 1-20 parts of cistanche deserticola, 1-12 parts of oriental water chestnuts, 1-6 parts of cimicifuga heracleifolia, and 1-8 parts of fructus aurantii.

3. The use according to claim 1, characterized in that The traditional Chinese medicine composition consists of the following components: 10-15 parts of angelica sinensis, 7-10 parts of cyperus rotundus, 7-10 parts of cistanche deserticola, 5-8 parts of oriental water chestnuts, 2-3 parts of cimicifuga heracleifolia, and 3-5 parts of fructus aurantii.

4. The use according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following components: 14.92 parts of angelica sinensis, 7.46 parts of cyperus rotundus, 9.33 parts of cistanche deserticola, 5.60 parts of oriental water chestnuts, 2.61 parts of cimicifuga heracleifolia, and 3.73 parts of fructus aurantii.

5. The use according to any one of claims 1 to 4, characterized in that: The medicine also includes pharmaceutically acceptable excipients or additives.

6. The use according to claim 5, characterized in that The pharmaceutically acceptable excipients or additives include fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, and bases.

7. The use according to claim 5, characterized in that The medicine is selected from decoctions, granules, capsules, tablets, pills, oral liquids, tinctures, syrups, suppositories, gels, sprays, and injections.

8. The use according to any one of claims 1 to 4, characterized in that: The preparation of the traditional Chinese medicine composition comprises the following steps: taking six medicinal materials, namely, angelica sinensis, cyperus rotundus, cistanche deserticola, oriental water chestnut, cimicifuga heracleifolia, and fructus aurantii, adding 8 times the amount of water, performing reflux extraction for 40 minutes, filtering, and concentrating the filtrate into an extract.

9. The use according to any one of claims 1 to 4, characterized in that: The drug is selected from granules, and the preparation of the granules comprises the following steps: a. Take angelica, Achyranthes, Cistanche, Alisma, Cimicifuga, Citrus aurantium six herbs, add 8 times the amount of water, reflux extraction for 40 minutes, filter, and concentrate the filtrate into an extract; b. Take the above extract, spray dry it, grind it into a fine powder, mix it, and spray-dry the fine powder. Add an appropriate amount of dextrin and steviol glycosides and granulate it.

10. Use of a traditional Chinese medicine composition in the preparation of a drug for promoting intestinal motility, intestinal barrier protection and / or for treating intestinal obstruction inflammatory response, the traditional Chinese medicine composition being prepared by weight from the following components: 1-100 parts of angelica sinensis, 1-100 parts of Achyranthes bidentata, 1-100 parts of Cistanche deserticola, 1-100 parts of Alisma orientalis, 1-100 parts of Cimicifuga heracleifolia, and 1-100 parts of Cimicifugae.

Images